Multiple myeloma gammopathies

Systemic amyloidosis: moving into the spotlight



Systemic amyloidosis is a rare but increasingly recognised disease that is heterogeneous in presentation. Early diagnosis, whilst imperative, remains challenging but can improve prognosis and limit organ dysfunction. An increased repertoire of diagnostic imaging and histological techniques are becoming mainstream and promise to aid early diagnosis. Better risk stratification, via biomarkers and cytogenetics, has improved multidisciplinary treatment decisions. The use of novel agents has improved treatment efficacy, which translates into survival benefit. Newer strategies targeting pre-deposited amyloidogenic protein are under investigation. The current paper reviews available data relating to the most recent advances in the field of systemic amyloidosis.


Systemic amyloidosis is characterised by the misfolding of autologous proteins, which aggregate into an abnormal fibrillar form and deposit in organs leading to progressive dysfunction [1]. Whilst AL amyloidosis is still considered a rare disease, an epidemiological study in the United States reports a doubling in prevalence from 15.5 cases per million in 2007 to 40.5 cases per million in 2015 despite a stable incidence [2] reflecting key advances in detection, response assessment and the availability of novel agents. Whilst AL amyloidosis predominates, the recognition of wild-type transthyretin amyloidosis (wtATTR) is rapidly increasing. In contrast, the declining prevalence of AA amyloidosis is indicative of key advances in the control of underlying inflammatory conditions (e.g. rheumatoid arthritis and inflammatory bowel disease). The key subtypes of amyloidosis are summarised in Table 1.

Table 1 Key subtypes of amyloidosis.

In this paper, we review the changing demographics of the disease and address the key issue of early recognition. We discuss the value of the latest available novel therapies and evaluate emerging treatments, which may become available in the future.

Recognition of amyloidosis

Amyloidosis is characterised by progressive dysfunction of the heart, liver and kidneys, which interplays with variable damage to nerves, soft tissue and the gastrointestinal tract. Early symptoms are non-specific (e.g. peripheral oedema, dyspnoea) leading to diagnostic difficulties and consequent delays. The patient pathway to diagnosis is varied—nephrology, haematology and cardiology dominate this pathway although most patients have seen a median of 4 specialists prior to diagnosis. One-third experience delays of ≥1 year from symptom onset [3]. Other common presenting features include a bleeding diathesis, paresthesia, postural hypotension and macroglossia.

In each of the relevant specialities, there are specific clues to assist early recognition. In the haematology clinic, all patients with systemic AL amyloidosis have an underlying plasma cell (or B lymphoid) dyscrasia. Crucially, we know from a seminal study that a monoclonal immunoglobulin was present in all samples taken ≤4 years before diagnosis [4] presenting a clear window of opportunity to identify amyloidosis early via vigilant assessment. In the cardiology clinic, the syndrome of heart failure with preserved ejection fraction (HFpEF), particularly if associated with renal impairment, carpal tunnel syndrome (CTS) or an unexpectedly high N-terminal pro-B type natriuretic peptide (NT-proBNP), should prompt investigation for amyloidosis. The triad of CTS, spinal stenosis and HFpEF is highly suggestive of wild-type ATTR amyloidosis. Patients presenting with renal involvement often have the easiest diagnostic pathway as progressive renal impairment with proteinuria is identified early in primary care. The challenge here is to separate patients who need prompt referral to nephrology from a large population of older adults with renal impairment due to other co-morbidities. A careful family history in patients with neuropathic, cardiac (e.g. hereditary ATTR) or renal (e.g. fibrinogen alpha-chain amyloidosis) amyloidosis is imperative. In all settings, the presence of CTS is a seriously underappreciated clue to a future diagnosis of amyloidosis.

Despite an increased prevalence, systemic AL amyloidosis remains a rare disease. In patients with incidental asymptomatic amyloid deposits, the risk of developing systemic disease in the longer term remains unclear. Wild-type ATTR amyloidosis, although still a rare disease, appears to be substantially under-diagnosed. A study of patients with HFpEF suggested that 13% may have underlying wtATTR amyloidosis [5]. Wild-type ATTR amyloidosis appears to be on course to emerge as a major public health issue in the elderly.

Steps to a diagnosis of amyloidosis

The diagnosis of amyloidosis is made by demonstration of amyloid deposition histologically or via a diagnostic imaging modality with high specificity for amyloidosis. The former method has the advantage of allowing for both confirmation of the diagnosis and, critically, typing amyloid deposits.

Histological diagnosis of amyloidosis

Congo red staining, exhibiting characteristic birefringence under cross polarised light, remains the gold standard. The biopsy of an affected organ has the highest yield but carries a bleeding risk. Sampling of abdominal fat, via aspiration, is a preferred low risk alternative and detects amyloid deposition in over three quarters of cases of cardiac AL amyloidosis when undertaken and reported in experienced centres. This method is less sensitive for the detection of both hereditary (45% sensitivity) and wild-type (15% sensitivity) ATTR [6]. Laboratories must be vigilant for false positive and negative results, which may compromise diagnosis.

Amyloid referral centres routinely undertake typing of amyloid fibrils but cost and complexity are major deterrents for regional hospitals. Furthermore, the need for typing amyloid deposits in all cases remains a contentious issue. In cases of a clear free light chain excess, soft tissue amyloid (a pathognomonic feature of AL amyloidosis) and multi-organ involvement, one could conceivably omit typing. On the contrary, typing is critically important in cases of isolated renal or cardiac involvement to exclude non-AL amyloidosis. The use of laser microdissection and capture of Congo red positive tissue followed by protein identification by mass spectrometry and bioinformatics (LCMS), greatly improves sensitivity and specificity of amyloid fibril typing [7]. This approach is strongly recommended unless there is a well-established programme of routine amyloid immunohistochemistry or immuno-electron microscopy to characterise the amyloidogenic protein. LCMS has led to the detection of multiple new amyloidogenic proteins in addition to providing greater diagnostic accuracy. A newer technique, independent of the need for Congo red staining, relies on detection of both the molecular weight and spatial distribution of biomolecules and the use of a novel peptide filter (MALDI-IMS MSI) to classify amyloid proteins in a less time and sample consuming manner [8].


Echocardiography is a widely available first line method to identify patients who warrant further work up but is relatively non-specific. Two highly specific methods have changed the imaging approach to amyloidosis: cardiac magnetic resonance imaging (CMR) and bone scintigraphy tracer imaging. CMR is highly specific for the diagnosis and may have a role in monitoring serial changes via the hallmark pattern of late gadolinium enhancement [9]. Extracellular amyloid deposits lead to a marked increase in the myocardial extracellular volume (ECV), which can be measured by specific MRI sequences to provide a quantitative estimate of the myocardial amyloid burden. ECV, along with pre-contrast T1 mapping, appears to correlate with established markers of disease severity, such as the serum biomarkers, NT-proBNP and Troponin T (TnT), and predicts mortality [10]. Furthermore, myocardial amyloid regression can be accurately documented by a reduction in T1 and ECV—a novel modality to track the progress of a patient following treatment [11]. On CMR, T2 imaging is a marker of tissue oedema and can act as a potential myocardial “biomarker” of amyloid oligomer or light chain proteotoxicity [9]. Improvement in cardiac amyloid can be seen via these modalities as pictured in Fig. 1a. Novel CMR methods are redefining our ability to track cardiac amyloid with clear prognostic value.

Fig. 1: Imaging modalities in amyloidosis.

a Cardiac MRI modalities demonstrating improvement following a complete response to chemotherapy. Image courtesy of Dr Ana Martinez-Naharro and Dr Marianna Fontana. b Serial SAP scintigraphy demonstrating regression of amyloid in the liver over a 5 year period.

The use of radiolabelled bone seeking tracers such as 99mtechnetium-pyrophosphate or 99mtechnetium-3,3-diphospono-1,2-propanodicarboxylic acid ([99mTc]-PYP or DPD) has transformed imaging for cardiac amyloidosis. These methods are sensitive for cardiac involvement in transthyretin amyloidosis, and in the absence of a monoclonal protein in serum or urine, grade 2 or 3 myocardial radiotracer uptake is considered diagnostic for ATTR amyloidosis [12]. However, in AL amyloidosis sensitivity is lacking. Imaging is positive in just 51% of patients with biopsy-proven cardiac AL amyloidosis[12]. 99mTc-DPD uptake has also been reported in apolipoprotein A-I amyloidosis [13].

Imaging to quantify the amyloidogenic protein load is a valuable diagnostic tool and can be used to monitor progress. 123Iodine-labelled serum amyloid P component scintigraphy is in routine clinical use at the UK NAC and is able to image visceral amyloid deposits in the liver, spleen, kidneys, adrenal glands and bones [14]. This method can track regression over time in patients who have responded to treatment as seen in Fig. 1b. However, this form of imaging is not useful for cardiac involvement and its availability is limited worldwide.

Positron emission tomography-based (PET) modalities have emerged as potentially useful tools to evaluate amyloid deposits using both 18F-florbetapir [15] (see Fig. 2a) and 11C-PiB [16] as tracers. A trend towards greater PET avidity in newly diagnosed patients and poor treatment responders with cardiac amyloidosis is reported [15]. Imaging with 18F-florbetapir appears to be highly sensitive and further studies are required to validate this technique. A new radiotracer, designated p5+14, is a synthetic, basic polypeptide with 45 amino acids and forms an α-helix in the presence of highly sulfated glycosaminoglycan and amyloid fibrils, resulting in specific multivalent electrostatic interactions. The peptide binds a variety of amyloid fibrils and can be visualised on PET imaging when bound to 124I (see Fig. 2b). It is currently under investigation in a first-in-man phase 1 study (NCT03678259).

Fig. 2: PET imaging in amyloidosis.

a PET-CT imaging using 18F-florbetapir as the tracer and demonstrating cardiac uptake in AL amyloidosis. b PET-CT image demonstrating uptake of p5+14 labelled with iodine-124 by amyloid in the liver. Image courtesy of Dr Jonathan Wall.

Figure 3 shows a suggested algorithm to make a definitive diagnosis of amyloidosis in suspected cases.

Fig. 3: Suggested algorithm of investigations to diagnose amyloidosis.

*1: Consider DNA testing for Gelsolin-type amyloidosis in the presence of cranial neuropathies and/or corneal lattice dystrophy, especially in the context of family history of similar symptoms. *2: Consider DNA testing for fibrinogen-alpha chain amyloidosis in the presence of renal (+/− liver) involvement, especially in the presence of a family history of renal failure. CTS carpal tunnel syndrome, MGUS monoclonal gammopathy of undetermined significance, MM multiple myeloma, Tc-DPD 99mtechnetium-3,3-diphosphono-1,2-propanodicarboxlyic acid, hATTR hereditary transthyretin amyloidosis, wt-ATTR wild-type transthyretin amyloidosis, Apo A-1 apolipoprotein A-1 amyloidosis, IHC immunohistochemistry, immuno-EM immune-electron microscopy, MS mass spectrometry.

Risk stratification

Biomarkers: initiation and opportunity

Cardiac involvement is the major determinant of prognosis in AL amyloidosis and consequently forms the basis of validated scoring systems e.g. Mayo 2010 based upon NT-proBNP, TnT and difference between involved and uninvolved light chains (dFLC) [17]. Although NT-proBNP has been validated as a marker of cardiac response following treatment [18], it is exquisitely sensitive to a large number of factors that affect fluid balance making serial monitoring challenging. Lately, it has been demonstrated that the depth of organ response for the heart, kidney and liver correlates with prolonged survival. This needs to be validated to update current organ response criteria in AL amyloidosis [19].

A number of biomarkers have been reported to have prognostic value as demonstrated in Fig. 4 [20,21,22,23,24,25,26,27]. This increasing pool of biomarkers (growth differentiation factor-15, proadrenomedulin, osteopontin, hepatocyte growth factor, soluble suppression of tumorgenicity 2, von Willebrand factor antigen, osteoprotegerin and immunoparesis) warrant further investigation in large case series’ with a view to providing a more accurate assessment of individual risk. At present, these novel markers have not been incorporated into routine practice.

Fig. 4: Novel biomarkers in AL amyloidosis: [20,21,22,23,24,25,26,27].

GDF-15 growth differentiation factor 15, sST2 soluble suppression of tumorgenicity 2, HGF hepatocyte growth factor, vWF:Ag von Willebrand factor antigen, OPG osteoprotegerin.

Measurement of the underlying clone and clonal markers

The monoclonal protein and serum free light chains (FLC) are the drivers of disease in AL amyloidosis but the underlying biology of the clonal plasma cells determines response to treatment, duration of response and outcomes at relapse.

Advances in light chain measurements

The development of assays to measure the total kappa and lambda FLC (both monoclonal and normal polyclonal FLC) were transformative in the management of AL amyloidosis. A number of such assays are now available but two methods (FreeliteTM by the Binding Site Group, Birmingham, UK and another immunoassay by Siemens Healthcare diagnostics, Germany) are most widely used. The assays use antibodies against hidden epitopes present on the light chain molecule. There are persisting challenges with antigen excess leading to non-linearity and resultant over or under estimation of the monoclonal protein. These assays continue to demonstrate a large coefficient of variance between centres [28]. However, the critical failing of the assays is their inability to distinguish between the monoclonal and polyclonal components making up the total reported measurement of the FLC, which limits utility of the FLC measurement in patients with low level disease.

Mass spectrometry can be applied in peripheral blood to identify the monoclonal component of the involved FLC (iFLC) as shown in Fig. 5. The Mayo group pioneered a matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF-MS), a simple and sensitive method to detect serum monoclonal proteins, called MASS-FIX. This is a robust, reliable and highly automated technique that can be easily adopted for high-throughput testing. The sensitivity is significantly greater than traditional electrophoresis and immunofixation. This method detected M-proteins in 18 patients (out of 257) with no monoclonal protein detectable by standard serum/urine immunofixation techniques [29]. Our group have further developed this modality using FLC beads and a MALDI-TOF-MS method to characterise monoclonal light chains, which is highly sensitive and can detect disease in patients whose clone is only detectable in bone marrow by flow cytometry-based minimal residual disease (MRD) testing [30]. Whilst these methods are not yet widely available, their use may allow for more accurate monitoring of patients and formulation of early treatment decisions in the future.

Fig. 5: Mass spectrometry of peripheral blood.

Mass spectrometry demonstrating (1) a monoclonal lambda light chain peak (2) a monoclonal and glycosylated kappa light chain peak.

Assessment of the plasma cell clone

The impact of clonal biology on patient management has been the focus of numerous recent studies. Coexistent hypercalcaemia, renal failure, anaemia or lytic bone lesions (CRAB criteria) and an increase in bone marrow plasma cells (>10%) define equally high-risk populations in patients with AL amyloidosis [31]. Furthermore, the presence of circulating plasma cells by multi-parametric flow cytometry at diagnosis adversely impacts OS (although this is overcome by a good response to chemotherapy of very good partial response [VGPR] or better) [32].

Cytogenetic abnormalities further risk stratify patients with AL amyloidosis. The largest cohort from the Mayo group reported t (11;14) in 49%, monosomy 13/del (13q) in 36% and trisomies in 26% by interphase fluorescence in situ hybridisation in 692 patients with AL amyloidosis [33]. The presence of t (11;14) seems to be associated with a poorer response to bortezomib in patients with favourable disease and possibly immunomodulatory (IMiD) agent based treatment [33] but improved complete response (CR) rates following autologous stem cell transplantation (ASCT) [34]. The German amyloid group demonstrated that a gain of Chr 1q21 is an adverse marker [35]. The biological basis of these findings remains unclear and needs further research to allow development of targeted therapies.

Whole exome sequencing has demonstrated 21 mutated genes in common between MM and AL amyloidosis whilst also identifying four recurrent mutations in AL amyloidosis patients: PCMTD1, C21orf33, NLRP12 and NRAS [36]. A second study of ten patients identified that recurrent mutations in ASB15, ASCC3 and HIST1H1E were associated with inferior OS [37]. A large genome-wide association study in 1229 patients identified single nucleotide polymorphisms at ten loci with rs9344 most significant; the cyclin D1 splice site, a promotor of t (11;14) [38]. Whilst there appears to be no unique genomic signature of AL amyloidosis per se, further genetic sequencing studies are needed to increase understanding of the drivers behind AL amyloidosis, provide prognostic information and identify targets for future therapies.


A multidisciplinary approach with involvement from cardiologists, nephrologists, neurologists and haematologists, as required, is crucial in patients with systemic amyloidosis. Stringent supportive therapy is critical. In cases of renal or cardiac involvement, key elements include careful fluid balance and patient education in monitoring blood pressure and fluid status. In AL amyloidosis, chemotherapy remains the mainstay of treatment whilst in ATTR amyloidosis, the recent licencing of gene-silencing and protein stabilising therapies are a landmark advancement in amyloid therapeutics. In the remainder of amyloid subtypes, management remains supportive.

AL amyloidosis

Aims of treatment and response assessment

Current treatment paradigms aim to suppress the plasma cell clone to reduce the production of light chain immunoglobulins thus halting amyloid deposition and allowing for a gradual organ response and improved survival. A rapid haematological response is associated with improved outcomes in patients with advanced disease [39]. The advantage of a particular choice of cytotoxic treatment must be balanced against the patient’s baseline organ function, which may be significantly compromised as a result of amyloid deposition. Standardised assessment of disease status is key to inform treatment intensity and choice. Over the last decade, it has become apparent that deeper responses improve outcomes. Reduction of the iFLC to <20 mg/L or dFLC to <10 mg/L translates to superior organ responses and OS, over and above a CR by traditional haematological response criteria [40, 41]. A small proportion of patients present with a dFLC of ≤50 mg/L, which poses a challenge in terms of disease tracking.

Assessment of MRD, by flow cytometry or next generation sequencing (NGS), represents a more sensitive method to determine depth of response. Following treatment, the presence of ≥0.1% monoclonal plasma cells negatively impacts both progression free and overall survival [42]. In patients achieving a CR, the detection of bone marrow plasma cells by flow cytometry negatively impacts progression-free survival (PFS) [43]. Patients who are MRD positive by flow cytometry have impaired organ recovery [44]. The role of both flow cytometry and NGS remains unclear and require further study before incorporating their use into routine treatment decisions.

Plasma cell directed therapy

Autologous stem cell transplantation

ASCT remains a standard of care in selected fit patients with AL amyloidosis. Key improvement in patient selection has reduced treatment related mortality (TRM), a major limitation of early studies (important exclusion criteria listed in Table 2). Lately, a US registry study reported a decrease in 100-day TRM from 20% to 5% in patients treated in 1995–2000 and 2007–2012 respectively [45]. Our group reported a PFS of 54 months with no TRM in 22 patients who were considered transplant ineligible at presentation due to organ dysfunction, predominantly advanced cardiac involvement [46]. Whilst ASCT leads to durable remissions in patients achieving a CR or VGPR (OS of 7.6 years in series from Boston [47] and 11.6 years in UK series [46]), a CR is seen in only a third of all patients (34.8% in the Boston series [47]).

Table 2 Exclusion criteria for ASCT.

Two approaches have been considered to overcome this limitation of transplantation—induction chemotherapy and post-transplant consolidation. The use of bortezomib-based induction chemotherapy prior to ASCT has demonstrated CR rates of 63% with median PFS and OS not reached at 36 months [48]. Furthermore, a good response to bortezomib-based induction chemotherapy may lead to an organ response and reversal of ASCT exclusion criteria such as high cardiac biomarkers and poor performance status. In this scenario, a PFS of 54 months is reported in 22 patients without TRM [49]. ASCT may still be of value for patients with primary refractory disease after bortezomib induction therapy (PR or worse), with one small study reporting a 42% CR rate in 12 refractory patients [50]. Conversely, bortezomib consolidation therapy for patients in a VGPR or worse following ASCT alone, led to one-third achieving a CR subsequently [51] The optimal timing, nature and duration of additional therapy around ASCT remains unclear and presents an ongoing dilemma.

Standard chemotherapeutic approaches

Bortezomib is established as the mainstay of upfront treatment for the majority of patients with AL amyloidosis (Treatment Combinations in Table 3). The benefit of bortezomib–melphalan–dexamethasone was clearly demonstrated in a recent randomised phase III trial of 100 newly diagnosed patients with AL amyloidosis; improving CR/VGPR rates from 28% to 53% [52]. The most widely used regimen is CyBorD (combination of cyclophosphamide, bortezomib and dexamethasone). A European collaborative study of 230 patients demonstrated efficacy of CyBorD, reporting haematological, renal and cardiac response rates of 60%, 25% and 17%, respectively [53]. We have recently reported the outcomes of 915 patients with haematological, renal and cardiac response rates of 65%, 15.4% and 32.5%, respectively [54]. A rapid response with bortezomib-based therapy can significantly improve outcomes even in advanced cardiac patients (median OS improving from 5 m to 26 m in patients achieving a CR/VGPR by end of 1 month [39]). Bortezomib is the key drug in newly diagnosed AL with a recent report from the Greek amyloid group questioning the additional benefit of cyclophosphamide within CyBorD as it does seem to not significantly improve efficacy or survival [55].

Table 3 Treatment regimens for patients with AL amyloidosis.

IMiDs are routinely used in relapsed AL amyloidosis. The efficacy of lenalidomide–dexamethasone was first reported over 10 years ago [56, 57]. The Greek amyloid group recently demonstrated 51% haematological, 22% renal, 7% liver and 3% cardiac response rates to lenalidomide as salvage therapy [58]. In combination with melphalan and dexamethasone, haematological response rate was similar (58%) but only 8% achieved an organ response. This combination was highly toxic with 40% of patients dying due to acute cardiac events within months of treatment and a median OS of 1.75 months for stage III patients [59]. However, a study by the German group of lenalidomide, melphalan and dexamethasone in untreated transplant ineligible patients yielded better outcomes with a 68% haematological response and 48% organ response. In this group, median OS was 67.5 months. There was just one cardiac death after three cycles of chemotherapy despite 18 patients (36%) having stage III disease [60]. However, stage III patients still had a PFS of <12 months and the proportion of patients with stage IIIb disease was not specified. In both studies, the lenalidomide dosing (10 mg) and frequency was the same but the German group used a lower melphalan dose of 0.15 mg/kg as opposed to 0.18 mg/kg, which may have had some impact on the lesser toxicity reported.

Pomalidomide is rapidly acting (responses in ~1 month) and has shown a survival advantage as salvage therapy in heavily pre-treated patients [61,62,63]. A recent report demonstrated 66% haematological response with a median PFS of 15 months although no patients achieved a CR with pomalidomide alone [64]. Further evaluation of pomalidomide as part of combination chemotherapy is required to assess its efficacy in this setting although toxicity may be an issue in heavily pre-treated patients with our study reporting a 41.1% (7/19 evaluable patients) discontinuation rate due to adverse events in patients with a median of 4 prior lines of therapy.

The addition of clarithromycin to IMiD-based therapies has demonstrated some efficacy. One study examined 49 patients with either multiple myeloma (n = 32) or AL amyloidosis (n = 17) demonstrating a 94% haematological and 47% organ response rate in patients with AL amyloidosis (35% haematological response prior to the addition of clarithromycin in the same cohort) [65]. However, the recent report of increased mortality when clarithromycin was added to lenalidomide–dexamethasone in multiple myeloma [66] suggests a need for caution when using this agent in AL amyloidosis.

Novel chemotherapeutic agents

Proteasome inhibitors

Carfilzomib and Ixazomib are newer PIs with limited evidence for use in AL amyloidosis. Carfilzomib is associated with lesser neurotoxicity compared to bortezomib and has been examined as salvage therapy (given twice weekly) in a multi-centre phase I/II study demonstrating a haematological response in 63% and an organ response in 21% (five patients: three renal, one gastrointestinal, one liver). However, toxicity was significant with 71% patients experiencing grade 3/4 toxicity, which was most commonly cardiac or pulmonary [67]. It appeared to be better tolerated with higher responses in a recently concluded phase I study of weekly carfilzomib with thalidomide–dexamethasone [68]. Further combinations of weekly carfilzomib with newer IMiDs or daratumumab need to be explored.

Ixazomib is an oral PI, which has also been examined in the relapsed/refractory setting. Sanchorawala et al. reported a 52% haematological response and 56% organ response (50% cardiac, 50% renal) with a median PFS of 14.8 months [69]. However, a recent phase III clinical trial of ixazomib–dexamethasone compared to a regimen of physicians choice in relapsed AL amyloidosis did not meet the primary end point in a planned intern analysis. The results demonstrate improved PFS (11.2 vs. 7.4 months, p = 0.043), time to next treatment (26.5 vs. 12.5 months, p = 0.027) and prolonged time to vital organ deterioration (34.8 vs. 26.1 months, p = 0.012) with Ixazomib–dexamethasone compared to physician’s choice [70]. These newer PIs have promising advantages in patients with neurotoxicity and those who would benefit from an oral agent to minimise visits to their haematology centre but further work is required to fully characterise their efficacy and toxicity in larger groups of patients.

Daratumumab—a transformative role in AL amyloidosis

Daratumumab, an anti-CD38 monoclonal antibody, is showing remarkable promise in AL amyloidosis. In heavily pre-treated patients, inclusive of 72% with cardiac involvement, one study demonstrated a 76% haematological response rate (36% CR) with a median response time of 1 month [71]. A recent publication from the Mayo clinic reported impressive haematological response rates of 78% with daratumumab monotherapy and 88% with combination therapy (addition of bortezomib, lenalidomide or pomalidomide) [72]. Best cardiac response rate was similar in both groups but occurred earlier (8.3 vs. 14.6 months) in the monotherapy group. The treatment was well tolerated with 22% experiencing significant infusion reactions.

The ANDROMEDA trial (NCT03201965) is examining frontline daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone. In a run-in cohort of 28 patients treated with CyBorD-Daratumumab, the overall haematological response rate was 96% (54% CR). At a median follow-up of 341 days, all patients in CR continued to respond to treatment [73]. This regimen used subcutaneous Daratumumab and grade 1 infusion related reactions were seen in two patients only. The provisional response rates are incredibly promising and suggest that the combination of daratumumab with CyBorD could represent a significant advance in the treatment of AL amyloidosis assuming results are confirmed in the ongoing phase III study.


BCL-2 is an anti-apoptotic protein expressed at higher levels in patients with plasma cell dyscrasias harbouring the t (11; 14) translocation. Consequently, the inhibition by venetoclax, a BCL-2 inhibitor, to treat the condition is logical in AL amyloidosis where half of all patients harbour this translocation. Of seven patients treated with venetoclax for AL amyloidosis (alone or in combinations including bortezomib and lenalidomide), two achieved CR and three achieved VGPR. However, two patients discontinued therapy (one cytopenia, one suboptimal response) and four patients suffered gastrointestinal side effects [74]. A further report of two heavily pre-treated patients, receiving venetoclax in combination with a PI, documented a CR in both patients. One patient stopped treatment due to pneumonia after cycle 2 whilst a second stopped treatment due to discontinuation of the BELLINI trial. The former has remained in CR, without further treatment, almost a year later [75]. Finally, a third series of venetoclax ± bortezomib in relapsed-refractory cardiac AL amyloidosis presented evaluable outcomes in 4/7 patients (two received 1 cycle only, one died of pneumonia after cycle 1) with a 50% response rate sustained at 76 and 713 days [76]. These early results are promising but a degree of caution is required given early toxicity data. A phase 1 trial aiming to enrol 25 patients to receive venetoclax is underway (NCT03000660).

Amyloid fibril-directed therapy and challenge of trial end points

AL amyloidosis

NEOD001, a drug that binds amyloidogenic light chains and promotes phagocytic clearance in vitro [77], failed to show efficacy in prospective trials and development has been discontinued. The PRONTO study used cardiac best response via NT-proBNP as a primary endpoint despite the variability of this biomarker. Furthermore, NT-proBNP increases after chemotherapy in 71% of patients at 6 months [78] thus early measurements can lead to false positive results. Whilst NT-proBNP does predict clinical outcome [18], these factors highlight the challenges associated with its use as a study endpoint. Analysis of the Phase 3 VITAL study of NEOD001 plus standard of care suggests a survival benefit in high-risk Mayo Stage IV patients’ thus additional clinical studies of NEOD001 may be warranted in the future [79].

A phase 1 trial of (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) also known as miridesap, with dezamizumab, a humanised monoclonal anti-SAP antibody, demonstrated hepatic and renal clearance with reduction of the splenic amyloid load and improved hepatic function [80]. However, the trial assessing this combination (NCT03044353) in cardiac amyloidosis was stopped after a data review cited an unfavourable risk-benefit. The chimeric fibril-reactive monoclonal antibody, CAEL-101 (formally 11-1F4), has also been shown to be safe in a phase 1 setting with interim analysis reporting reduction in the amyloid burden with associated rapid improvement in organ function [81]. A randomised phase 2/3 trial further assessing CAEL-101 is planned in 2020.

Further work aiming to better evaluate the structure and pathogenesis of light chain protein misfolding is underway. Two studies have used cryo-electron microscopy mapping of tissue extracted fibrils from patients with AL amyloidosis to provide insight into the mechanism of protein misfolding. This work may lead to the development of novel ligands providing a foundation for future amyloid fibril-directed therapy [82, 83].

Doxycycline interferes with amyloid fibril formation in mouse models and, as such, a small retrospective study suggested that doxycycline added to standard therapy reduced early cardiac mortality but did not impact haematological response rate [84]. A further trial evaluating the addition of doxycycline to standard therapy in patients receiving bortezomib-based therapy for cardiac AL amyloidosis (NCT03474458) is underway. Publication of the DUAL study is awaited (NCT02207556)—a phase 2 study investigating the use of prolonged doxycycline used to upgrade response in AL amyloidosis.

RNA inhibitors and protein stabilisers in ATTR and AL amyloidosis

In hereditary ATTR (hATTR), liver transplantation was the historical standard of care [85] whilst wtATTR amyloidosis had no disease modifying treatment. Two strategies have transformed the therapeutic scenario in ATTR amyloidosis. Transthyretin stabilisers have been used as a means of slowing disease progression with some success. Diflunisal, a non-steroidal anti-inflammatory drug, and tafamidis, a thyroxine-like TTR-stabiliser, reduce neurological progression and improve quality of life scores in patients with hATTR [86, 87]. Tafamidis is licenced for this indication in Europe. A phase III study demonstrated significant survival benefit for patients with cardiac ATTR treated with tafamidis which has led to the drug being the first licensed treatment for this indication. Exciting gene-silencing therapies (patisaran [88] and inotersen [89]), selectively switching off transthyretin production, are now licenced for patients with neuropathic hATTR amyloidosis. Both agents have demonstrated highly significant improvements in neurological and quality of life scores. Patisiran also decreased mean left ventricular wall thickness, global longitudinal strain, NT-proBNP and adverse cardiac outcomes [90] suggesting an effect on patients with ATTR and associated cardiac involvement. Longer acting gene silencers (vutrisiran) and more potent transthyretin stabilisers (AG-10) are in clinical trials.

AL amyloidosis has trailed ATTR in these crucial therapeutic aspects. Recently, high-throughput screening and characterisation identified several small molecules that kinetically stabilise FLC by binding at the V-domain–V-domain interface in both kappa and lambda light chains providing the first step to a potential FLC stabilising approach [91]. Whilst pre-clinical work suggests potential in RNA inhibitors in reducing FLC production [92], this remains challenging to translate into in vivo models.

Conclusion and future directions

Recent advances in the diagnosis and treatment of amyloidosis, hold promise. At present, there are 125 active trials relating to amyloidosis ( reinforcing the notion that systemic amyloidosis is truly moving into the spotlight. Early detection remains a critical barrier to improving outcomes. Early adoption of amyloid specific imaging has led to a marked increase in the detection of wtATTR amyloidosis. Use of new methods to detect monoclonal protein in the serum will help both diagnosis and monitoring during treatment. In AL amyloidosis, assessment of response and tracking of organ damage due to amyloid deposits continues to improve whilst new MRD based methods may be used to detect early relapse and initiate next line therapy prior to the deposition of significant further amyloidogenic protein and associated organ dysfunction.

Rapid reduction in amyloidogenic light chains to preserve organ function in AL amyloidosis is critical. Risk stratification to direct therapy has improved outcomes in high-risk AL patients. Both novel agents and new combinations of therapies show promise in achieving rapid responses and improving survival with a number of clinical trials underway investigating these agents. There have been significant therapeutic advances in ATTR treatment, which may change the disease trajectory. Organ toxicity limits life expectancy in both AL and ATTR amyloidosis. The development of treatments that directly remove amyloidogenic protein from the circulation or accelerate clearance of tissue amyloid deposits, whist showing tantalising promise, still remains a horizon to be reached.


  1. 1.

    Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–96.

  2. 2.

    Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2:1046–53.

  3. 3.

    Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32:920–8.

  4. 4.

    Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014;32:2699–704.

  5. 5.

    Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–94.

  6. 6.

    Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38:1905–8.

  7. 7.

    Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR III, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009;114:4957–9.

  8. 8.

    Winter M, Tholey A, Kristen A, Rocken C. MALDI mass spectrometry imaging: a novel tool for the identification and classification of amyloidosis. Proteomics. 2017;17:1700236.

  9. 9.

    Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71:2919–31.

  10. 10.

    Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36:244–51.

  11. 11.

    Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. Regression of cardiac al amyloid by cardiovascular magnetic resonance. Circulation. 2016;134:A14407.

  12. 12.

    Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.

  13. 13.

    Quarta CC, Obici L, Guidalotti PL, Pieroni M, Longhi S, Perlini S, et al. High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid. 2013;20:48–51.

  14. 14.

    Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens. 2002;11:649–55.

  15. 15.

    Manwani R, Page J, Lane T, Burniston M, Skillen A, Lachmann HJ, et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid. 2018;25:247–52.

  16. 16.

    Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using (11)C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45:452–61.

  17. 17.

    Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30:989–95.

  18. 18.

    Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30:1979–86.

  19. 19.

    Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018;32:2240–9.

  20. 20.

    Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, et al. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid. 2011;18:216–21.

  21. 21.

    Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018;131:1568–75.

  22. 22.

    Kastritis E, Gavriatopoulou M, Dimopoulos MA, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, et al. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. Blood Cancer J. 2015;5:e319.

  23. 23.

    Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M, Komitopoulou A, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016;128:405–9.

  24. 24.

    Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015;90:524–8.

  25. 25.

    Abraham J, Desport E, Rigaud C, Marin B, Bender S, Lacombe C, et al. Hepatocyte growth factor measurement in AL amyloidosis. Amyloid. 2015;22:112–6.

  26. 26.

    Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, et al. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis. Amyloid. 2014;21:202–10.

  27. 27.

    Sachchithanantham S, Berlanga O, Alvi A, Mahmood SA, Lachmann HJ, Gillmore JD, et al. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis. Br J Haematol. 2017;179:575–85.

  28. 28.

    Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51:528–42.

  29. 29.

    Milani P, Murray DL, Barnidge DR, Kohlhagen MC, Mills JR, Merlini G, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017;92:772–9.

  30. 30.

    Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, et al. A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis. Blood Cancer J. 2019;9:16.

  31. 31.

    Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319–24.

  32. 32.

    Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, et al. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. 2018;32:1421–6.

  33. 33.

    Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017;31:1562–9.

  34. 34.

    Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594–602.

  35. 35.

    Bochtler T, Hegenbart U, Kunz C, Benner A, Seckinger A, Dietrich S, et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014;21:9–17.

  36. 36.

    Walker BA, Rowczienio D, Boyle EM, Wardell CP, Sachchithanantham S, Baginska A, et al. Exome sequencing to define a genetic signature of plasma cells in systemic al amyloidosis. Blood. 2013;122:3098.

  37. 37.

    Huang XF, Jian S, Lu JL, Shen KN, Feng J, Zhang CL, et al. Genomic profiling in amyloid light-chain amyloidosis reveals mutation profiles associated with overall survival. Amyloid. 2020;27:36–44.

  38. 38.

    da Silva Filho MI, Forsti A, Weinhold N, Meziane I, Campo C, Huhn S, et al. Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Leukemia. 2017;31:1735–42.

  39. 39.

    Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018;103:e165–8.

  40. 40.

    Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, et al. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. 2019;33:527–31.

  41. 41.

    Manwani R, Sharpley F, Mahmood S, Sachchithanantham S, Lachmann H, Gillmore J, et al. Achieving a difference in involved and uninvolved light chains (dFLC) of less than 10mg/L is the new goal of therapy in systemic AL amyloidosis: analysis of 916 patients treated upfront with bortezomib-based therapy. Blood. 2018;132:3262.

  42. 42.

    Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017;129:82–7.

  43. 43.

    Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK. The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia. 2018;32:1243–6.

  44. 44.

    Palladini GMM, Basset M, Russo F, Milani P, Foli A, Merlini G. Persistence of minimal residual disease by multiparameter flow cytometry can hinder recovery of organ damage in patients with AL amyloidosis otherwise in complete response. Blood. 2016;128:3261.

  45. 45.

    D’Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33:3741–9.

  46. 46.

    Sharpley F, Petrie, A, Mahmood, S, Sachchithanantham, S, Lachmann, HJ, Gillmore, JD, et al. A twenty-four year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 2019;187:642–52.

  47. 47.

    Sanchorawala V, Sun FG, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126:2345–7.

  48. 48.

    Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun FG, Sloan JM, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain annyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21:1445–51.

  49. 49.

    Manwani R, Hegenbart U, Mahmood S, Sachchithanantham S, Kyriakou C, Yong K, et al. Deferred autologous stem cell transplantation in systemic AL amyloidosis. Blood Cancer J. 2018;8:101.

  50. 50.

    Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy. Bone Marrow Transplant. 2017;52:936–7.

  51. 51.

    Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, et al. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2017;31:136–42.

  52. 52.

    Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. A randomized phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood. 2016;128:646.

  53. 53.

    Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015;126:612–5.

  54. 54.

    Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271–80.

  55. 55.

    Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, et al. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer J. 2017;7:e570.

  56. 56.

    Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007;109:465–70.

  57. 57.

    Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007;109:492–6.

  58. 58.

    Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, et al. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. Amyloid. 2018;25:234–41.

  59. 59.

    Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, et al. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica. 2013;98:1593–9.

  60. 60.

    Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up. Haematologica. 2017;102:1424–31.

  61. 61.

    Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood. 2012;119:5397–404.

  62. 62.

    Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. Blood. 2016;128:1059–62.

  63. 63.

    Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017;129:2120–3.

  64. 64.

    Sharpley FA, Manwani R, Mahmood S, Sachchithanantham S, Lachmann H, Gilmore J, et al. Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. Br J Haematol. 2018;183:557–63.

  65. 65.

    Shaulov A, Ganzel C, Benyamini N, Barshay Y, Goldschmidt N, Lavie D, et al. Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy. Am J Hematol. 2017;92:131–5.

  66. 66.

    Puig NHM, Rosinol Dachs L, Gonzalez Garcia E, De Arriba F, Oriol A, Gonzalez-Calle V, et al. Randomized trial of lenalidomide and dexamethasone versus clarythromycin, lenalidomide and dexamethasone as first line treatment in patients with multiple myeloma not candidates for autologous stem cell transplantation: results of the GEM-Claridex clinical trial. Orlando, USA: American Society of Haematology; 2019.

  67. 67.

    Cohen AD, Landau H, Scott EC, Liedtke M, Kaufman JL, Rosenzweig M, et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. Blood. 2016;128:645.

  68. 68.

    Garg MHA, Jenner M, Kishore B, Lachmann HJ, Gillmore JD, Pitchford A, et al. A phase 1 study of carfilzomib-thalidomide-dexamethasone in patients with relapsed/refractory AL amyloidosis—catalyst trial results. Orlando, USA: American Society of Haematology Conference; 2019.

  69. 69.

    Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130:597–605.

  70. 70.

    Dispenzieri AKE, Wechalekar AD, Schonland SO, Kim K, Sanchorawala V, Landau HJ, et al. Primary results from the phase 3 tourmaline-AL1 trial of ixazomib-dexamethasone versus physician’s choice of therapy in patients (Pts) with relapsed/refractory primary systemic AL amyloidosis (RRAL). Orlando, FL, USA: American Society of Haematology 2019.

  71. 71.

    Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130:900–2.

  72. 72.

    Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33:531–6.

  73. 73.

    Comenzo RL, Kastritis E, Maurer M, Zonder J, Minnema MC, Wechalekar A, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (cybord) in patients with newly diagnosed amyloid light chain (AL) amyloidosis: updated safety run-in results of andromeda. Amsterdam: European Haematology Assocation; 2019.

  74. 74.

    Sidiqi MH, Saleh AS Al, Leung N, Alijama M, Jevremovic D, Gonslaves W, et al. Venetoclax for the treatment of translocation (11; 14) Al amyloidosis. Amsterdam: European Haematology Association; 2019.

  75. 75.

    Premkumar V, Comenzo R, Lentzsch S. Venetoclax in immunoglobulin light chain amyloidosis: is this the beginning or the end? Clin Lymphoma Myeloma Leuk. 2019;19:686–8.

  76. 76.

    Le Bras FDJ, Lemonnier F, Oghina S, Bodez S, Ladaique A, Maarek A, et al. Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis. J Clin Oncol. 2019;37:e19538.

  77. 77.

    Zago W, Renz M, Torres R, Dolan PJ, Barbour RM, Salmans JR, et al. NEOD001 specifically binds aggregated light chain infiltrates in multiple organs from patients with AL amyloidosis and promotes phagocytic clearance of AL aggregates in vitro. Blood. 2015;126:3016.

  78. 78.

    Gibbs SDJ, De Cruz M, Sattianayagam PT, Lachmann HJ, Gillmore JD, Hawkins PN, et al. Transient post chemotherapy rise in NT Pro-BNP in AL amyloidosis: implications for organ response assessment. Blood. 2009;114:712.

  79. 79.

    Gertz MACA, Comenzo RL, Du Mond C, Kastritis E, Landau HJ, Libby III EL, et al. Results of the phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for mayo stage IV patients. Orlando, FL, USA: American Society of Haematology; 2019.

  80. 80.

    Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med. 2018;10:3128.

  81. 81.

    Edwards CV, Gould J, Langer AL, Mapara M, Radhakrishnan J, Maurer MS, et al. Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid. 2017;24:58–9.

  82. 82.

    Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, et al. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun. 2019;10:1269.

  83. 83.

    Radamaker L, Lin YH, Annamalai K, Huhn S, Hegenbart U, Schonland SO, et al. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun. 2019;10:1103.

  84. 84.

    Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7:e546.

  85. 85.

    Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847–54.

  86. 86.

    Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67.

  87. 87.

    Merkies IS. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2013;80:1444–5.

  88. 88.

    Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.

  89. 89.

    Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.

  90. 90.

    Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139:431–43.

  91. 91.

    Morgan GJ, Yan NL, Mortenson DE, Rennella E, Blundon JM, Gwin RM, et al. Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proc Natl Acad Sci USA. 2019;116:8360–9.

  92. 92.

    Hovey BM, Ward JE, Soo Hoo P, O’Hara CJ, Connors LH, Seldin DC. Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther. 2011;18:1150–6.

  93. 93.

    Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641–54.

  94. 94.

    Kaku M, Berk JL. Neuropathy associated with systemic amyloidosis. Semin Neurol. 2019;39:578–88.

  95. 95.

    Westermark GT, Fandrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015;10:321–44.

  96. 96.

    Sethi S, Theis JD. Pathology and diagnosis of renal non-AL amyloidosis. J Nephrol. 2018;31:343–50.

  97. 97.

    Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36:1323–9.

  98. 98.

    Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, Lavatelli F, et al. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 2014;28:2311–6.

  99. 99.

    Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2007;109:457–64.

  100. 100.

    Mahmood S, Venner CP, Sachchithanantham S, Lane T, Rannigan L, Foard D, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Br J Haematol. 2014;166:842–8.

Download references

Author information



Corresponding author

Correspondence to Ashutosh D. Wechalekar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cohen, O.C., Wechalekar, A.D. Systemic amyloidosis: moving into the spotlight. Leukemia 34, 1215–1228 (2020).

Download citation